Search research articles
Contact Us
Filters
Showing results (1321-1330 of 1,553) with videos related to
Page
of 156
Sort By:
Cancer Research and Treatment
|
July 8, 2016
Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
Dong-Hoe Koo, Min-Hee Ryu, Kyoung-Mee Kim, et al.
Frontiers in Pharmacology
|
August 8, 2022
A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor
Qi Zhang, Ting Deng, Fen Yang, et al.
Eclinicalmedicine
|
January 18, 2024
Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial
Yakun Wang, Jifang Gong, Airong Wang, et al.
Journal of Gastroenterology and Hepatology
|
September 20, 2023
Lugol-unstained lesions location in the esophagus affects the detection rate of malignancy: a population-based study
Jing Qin, Mengfei Liu, Anxiang Liu, et al.
Nature Communications
|
May 11, 2026
The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial
Panpan Zhang, Zuoxing Niu, Hongqian Guo, et al.
Lancet (London, England)
|
August 24, 2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, et al.
Cancer Immunology, Immunotherapy : CII
|
April 28, 2023
Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma
Qi Zhang, Jian Zhang, Haijun Zhong, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
August 24, 2024
Persistence of Lugol-unstaining is Associated With an Increased Risk of Progression to Malignancy in the Esophagus
Mengfei Liu, Zeyu Yan, Zifan Qi, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
March 8, 2024
Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas
Jianwei Zhang, Hanxiao Chen, Junli Zhang, et al.
Cancer Immunology, Immunotherapy : CII
|
May 7, 2024
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer
Panpan Zhang, Zhendong Chen, Si Shi, et al.
Page
of 156
Search research articles
Search
Showing results (1321-1330 of 1,553) with videos related to
Sort By:
Page
of 156
Cancer Research and Treatment
|
July 8, 2016
Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
Dong-Hoe Koo, Min-Hee Ryu, Kyoung-Mee Kim, et al.
Frontiers in Pharmacology
|
August 8, 2022
A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor
Qi Zhang, Ting Deng, Fen Yang, et al.
Eclinicalmedicine
|
January 18, 2024
Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial
Yakun Wang, Jifang Gong, Airong Wang, et al.
Journal of Gastroenterology and Hepatology
|
September 20, 2023
Lugol-unstained lesions location in the esophagus affects the detection rate of malignancy: a population-based study
Jing Qin, Mengfei Liu, Anxiang Liu, et al.
Nature Communications
|
May 11, 2026
The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial
Panpan Zhang, Zuoxing Niu, Hongqian Guo, et al.
Lancet (London, England)
|
August 24, 2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, et al.
Cancer Immunology, Immunotherapy : CII
|
April 28, 2023
Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma
Qi Zhang, Jian Zhang, Haijun Zhong, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
August 24, 2024
Persistence of Lugol-unstaining is Associated With an Increased Risk of Progression to Malignancy in the Esophagus
Mengfei Liu, Zeyu Yan, Zifan Qi, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
March 8, 2024
Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas
Jianwei Zhang, Hanxiao Chen, Junli Zhang, et al.
Cancer Immunology, Immunotherapy : CII
|
May 7, 2024
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer
Panpan Zhang, Zhendong Chen, Si Shi, et al.
Page
of 156